DSM Venturing invests in Arecor innovative protein stabilization technology
The application of Arecor’s technology enables the development of new products that would not otherwise be possible and/or valuable competitive differentiation of marketed biopharmaceutical products. Many proteins, peptides or vaccines are too unstable in liquid form to develop ready-to-use drugs or are unstable at high concentrations. Arecor has developed a set of unique technologies to address these problems with the potential to revolutionize the development, use and distribution of the next generation of therapeutic medicines. The application of Arecor’s technology to develop differentiated formulations also extends to enhancing end-user convenience such as converting powders to ready to use liquid formulations for self-injection, replacing infusions with high concentration liquids that can be administered in a single injection, removal of cold-chain requirements. Moreover, the application of Arecors technology principles may lead to significant cost reductions in manufacturing.
Arecor is collaborating with a number of leading pharmaceutical and biotech companies to develop differentiated formulations of recombinant proteins, monoclonal antibodies, vaccines medical devices and diagnostics.
Arecor was spun out of Unilever Research in 2007. Unilever Ventures was the lead investor in previous financing rounds.
Arecor’s CEO Tom Saylor says: “We are well aware of DSM’s experience in pharmaceutical manufacturing and history of implementing innovative manufacturing technologies. We are happy to have DSM as a major investor which offers the potential to strengthen Arecor’s leadership in developing superior formulations of biological products."
Karen King, President of DSM Biologics says: “DSM is constantly seeking solutions to improve the manufacturing of biopharmaceuticals through our own innovations and through creative external collaborations and investments. The Arecor technology has the potential to create significant benefits to our clients and ultimately the patients.”
Pieter Wolters, Managing Director Venturing and Licensing at DSM says: “By investing in Arecor, DSM gains access to a potentially game-changing platform that may have a large effect on the bio-pharmaceutical industry. We are encouraged by the technology development as well as the quality and quantity of partners Arecor has contracted since its inception.”
Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into stabilization of biologics. Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products. Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation. As a simple reformulation, Arestat can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines. More information can be found at www.arecor.com.